Market Overview:

The fertility test market is experiencing rapid growth, driven by delayed parenthood and demographic shifts, rising prevalence of reproductive health disorders, and government initiatives and regulatory support. According to IMARC Group’s latest research publication, “Fertility Test Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033”, The global fertility test market size reached USD 584.38 Million in 2023. Looking forward, IMARC Group expects the market to reach USD 971.69 Million by 2032, exhibiting a growth rate (CAGR) of 5.52% during 2024-2032.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/fertility-test-market/requestsample

Our report includes:

• Market Dynamics
• Market Trends and Market Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Fertility Test Market

• Delayed Parenthood and Demographic Shifts

The primary driver for the fertility test market is the global shift toward delayed parenthood, particularly in developed and emerging economies. As individuals prioritize career advancement and higher education, the average age for first-time pregnancies has risen significantly, often exceeding 30 years in many regions. Since biological fertility naturally declines with age, there is an increased reliance on diagnostic tools to identify optimal conception windows. Recent data highlights that the average age of first-time mothers in several European and North American countries has shifted from 27.5 to 32.4 years over the last decade. This demographic trend has created a robust demand for ovulation prediction kits and fertility monitors. Furthermore, with nearly 1 in 6 people globally experiencing infertility, the necessity for early and frequent testing has moved from a clinical luxury to a standard component of proactive family planning.

• Rising Prevalence of Reproductive Health Disorders

A surge in reproductive health conditions, such as Polycystic Ovary Syndrome (PCOS) and endometriosis, is significantly propelling market expansion. PCOS, which affects approximately 10% to 15% of women of reproductive age, often leads to irregular ovulation, making standard conception efforts difficult without precise monitoring. To address this, companies like SPD Swiss Precision Diagnostics and Mira have developed advanced monitors that track multiple hormones, such as Luteinizing Hormone (LH) and Estrogen, to provide a more accurate fertile window for those with irregular cycles. Additionally, the increasing incidence of male infertility—often attributed to lifestyle factors like stress and obesity—has led to a greater uptake of male-specific testing products. Research indicates that infertility rates now affect roughly 12% of couples worldwide, forcing a transition toward comprehensive diagnostic kits that can be used within the privacy of the home.

• Government Initiatives and Regulatory Support

Strategic government interventions and global health guidelines are playing a crucial role in normalizing and subsidizing fertility diagnostics. In late 2025, the World Health Organization (WHO) released its first-ever global guideline for infertility, urging nations to integrate fertility care into national health strategies and make diagnostics more affordable. This has led to increased public funding for reproductive health awareness campaigns and the inclusion of testing services in universal healthcare packages in several jurisdictions. For instance, new federal proposals in the United States aim to mandate insurance coverage for a wider range of fertility services, while countries in the Asia-Pacific region are streamlining regulatory approvals for over-the-counter (OTC) medical devices. These initiatives lower the barrier to entry for consumers, shifting the market toward a more inclusive model where diagnostic tools are readily accessible through both public health systems and retail pharmacies.

Key Trends in the Fertility Test Market

• AI-Powered Personalized Monitoring

The integration of Artificial Intelligence (AI) into fertility monitors has transformed tracking from simple "yes/no" indicators to highly personalized health analytics. Modern devices now use machine learning algorithms to analyze a user’s unique hormonal patterns, predicting ovulation with up to 99% accuracy even for those with irregular cycles. For example, the Mira monitor and similar digital platforms utilize AI to quantify hormone concentrations in urine, syncing the data to smartphone applications that provide a visual "fertility score." This trend moves beyond traditional threshold-based testing, offering a bespoke approach that learns the user's specific baseline over several months. These systems can also flag potential hormonal imbalances early, allowing users to share detailed data logs with their physicians for more informed clinical consultations, effectively bridging the gap between at-home testing and professional medical advice.

• Expansion of At-Home Male Fertility Testing

Traditionally, the fertility market focused heavily on female diagnostics, but there is now a significant trend toward discreet, at-home male fertility testing. With male factors contributing to nearly half of all infertility cases, new products are empowering men to test sperm concentration and motility without visiting a clinic. Real-world applications include smartphone-connected devices like the Yo Sperm Test, which uses a mini-microscope attachment to allow users to view live sperm on their screens and receive an automated analysis of their reproductive health. This trend is gaining momentum due to the destigmatization of male infertility and the convenience of avoiding the "waiting room" experience. Numerical insights from recent market studies show that the male testing segment is one of the fastest-growing categories, as couples increasingly adopt a "dual-testing" approach at the beginning of their conception journey.

• Integration of Wearable IoMT Devices

The rise of the Internet of Medical Things (IoMT) has introduced wearable technology that monitors fertility markers 24/7, moving away from point-in-time urine tests. Wearable devices, such as the Ava bracelet or the Oura ring, track physiological signals like skin temperature, resting heart rate, and respiratory rate to identify the opening of the fertile window. These sensors take thousands of data points while the user sleeps, detecting the subtle thermal shift that occurs after ovulation. This trend is particularly popular among tech-savvy consumers who prefer a passive, "set-it-and-forget-it" method of tracking. The shift toward wearables reflects a broader movement in the healthcare industry toward continuous monitoring and preventative wellness, allowing individuals to manage their reproductive health with minimal daily effort while maintaining high levels of data accuracy.

We explore the factors driving the growth of the market, including technological advancements, consumer behaviors, and regulatory changes, along with emerging fertility test market trends.

Leading Companies Operating in the Global Fertility Test Industry:

• AdvaCare Pharma
• Babystart
• Church & Dwight Co., Inc.
• ExSeed Health
• Fairhaven Health
• LetsGetChecked
• Medical Electronic Systems
• Mira Fertility
• Modern Fertility
• Proov
• Quest Consumer Inc

Fertility Test Market Report Segmentation:

By Product Type:

• Ovulation Prediction Kits
• Fertility Monitors
• Male Fertility Testing Products

Ovulation prediction kits dominate the market in 2024 with 43.8% share due to their accessibility, ease of use, and high accuracy, driven by rising infertility issues and innovations in features.

By Mode of Purchase:

• OTC-based
• Prescription-based

OTC-based products lead the market with 68.7% share in 2024, favored for affordability and convenience, as consumers prefer at-home solutions for privacy and ease.

By Application:

• Female Fertility Testing
• Male Fertility Testing

Female fertility testing captures 83.7% of the market in 2024, driven by higher infertility concerns in women and the availability of diverse female-focused fertility products.

By End User:

• Hospitals
• Home Care Settings
• Fertility Clinics
• Others

Home care settings lead the market with 55.7% share in 2024, as consumers prefer privacy and convenience of at-home fertility tests, supported by technological advancements and easy access.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the largest market share of 38.6% in 2024, driven by rising infertility rates, strong awareness of reproductive health, and widespread availability of OTC fertility products.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302